Prothena Corporation

Prothena Corporation Liabilities

The The Liabilities of Prothena Corporation (PRTA) as of Oct 6, 2026 is 46.33 M USD. In the previous year, The Liabilities was 60.18 M USD — a change of -23.02% (lower).

Liabilities

46.33 MUSD

YoY

-23.02%

Last updated:

In 2026, Prothena Corporation's total liabilities amounted to 46.33 M USD, a -23.02% difference from the 60.18 M USD total liabilities in the previous year.

The Prothena Corporation Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
175.80 M USD
Jan 1, 2019
146.35 M USD
Jan 1, 2020
148.97 M USD
Jan 1, 2021
143.32 M USD
Jan 1, 2022
135.99 M USD
Jan 1, 2023
135.02 M USD
Jan 1, 2024
60.18 M USD
Jan 1, 2025
46.33 M USD
The Prothena Corporation Liabilities history
YEARLiabilitiesYoY
46.33 MUSD-23.02%
60.18 MUSD-55.43%
135.02 MUSD-0.72%
135.99 MUSD-5.11%
143.32 MUSD-3.79%
148.97 MUSD+1.79%
146.35 MUSD-16.75%
175.80 MUSD+97.22%
89.14 MUSD-5.74%
94.57 MUSD+284.96%
24.57 MUSD+72.68%
14.23 MUSD—
Access this data via the Eulerpool API

Prothena Corporation Stock analysis

What does Prothena Corporation do? Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014. Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions. Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis. A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017. Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication. Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases. Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Prothena Corporation's Liabilities

Prothena Corporation's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Prothena Corporation's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Prothena Corporation's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Prothena Corporation's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Prothena Corporation’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Prothena Corporation stock

The Liabilities of Prothena Corporation is 46.33 M USD in 2026.

The Liabilities of Prothena Corporation changed from 60.18 M USD to 46.33 M USD, representing a -23.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Prothena Corporation since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Prothena Corporation historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Prothena Corporation

All Key Metrics — Prothena Corporation